Leadership &Executive Team

Adir Trabelsi

Founder, Chief Investment Officer & Chief Risk Officer

Founder of BlackStar Capital. Investor, entrepreneur, and company builder with nearly two decades of legal, business, and securities investment experience. Architect of BlackStar’s mandate and portfolio construction, leading allocation, risk, and structure across direct assets, private opportunities, and tactical situations. Adir has led major corporate turnarounds in companies generating billions in revenue, combining legal expertise with deep operational and financial insight. A disciplined investor across securities and private markets, he has founded and scaled multiple ventures, building resilient structures that protect downside, compound capital, and deliver clean exits. Also serves as Chief Risk Officer, overseeing exposure, concentration, and stress-testing.

Dr. Gil Pogozelich

Partner, Capital & Origination

Chairman of BlackStar Capital. Expert in signal processing (PhD in Computer Science) with a Master’s in Law. Brings vast experience in life sciences, cyber, and technology investments. Managed an investment house dedicated to life sciences companies and worked closely with leading universities to commercialize research. Provides governance, oversight, and strategic guidance across sectors and vehicles.

Bernardo Fleming

Managing Director, Iberia — Real Assets

Leads origination, structuring, and operations for BlackStar’s real-asset mandates in Portugal and Iberia. Focused on cash-flowing assets and value-add repositioning with disciplined, on-the-ground execution.

Ariel Avram

Director of Capital Projects & Special Situations

Attorney and veteran operator with senior roles across large-scale build-outs, sports, and turnaround management. CEO of ROM (Geves Casings & Coverings 1997 Ltd.). Brings executional depth in complex capital projects, contracting, and multi-unit operations.

Adi Dagan

Venture Partner, Life Sciences Diligence & Origination

Biotech entrepreneur; ex-Founder/CEO of Arava Bio-Tech (2014). Led AR101—a dual-API topical wound-healing drug—through randomized clinical trials; deep expertise in insulin-signaling/PKC–driven epithelial regeneration. Evaluates life-science projects end-to-end (science, clinical, IP, regulatory) and originates qualified leads via Israeli and academic networks. Not the gaming/CRM or Cloudinary Adi Dagan.

Luís Paulo Sousa

Senior Advisor, Development Approvals - Portugal

Architect focused on planning permissions and regulatory approvals for institutional assets. Works directly with municipalities and public bodies to obtain Pedido de Informação Prévia, planning permission (licenciamento urbanístico), and Licença de Construção, navigating Plano Diretor Municipal, detailed plans, and special protection zones. Delivers technical due diligence for underwriting and pre-development—zoning and use, buildability, heritage constraints, fire safety, accessibility, and environmental compliance—aligning scope, budget, and schedule for institutional owners and lenders across Portugal.

Itamar Canari

Chief Financial Officer & Head of Capital Markets

Oversees finance, controls, compliance, liquidity, and reporting. Manages banking lines, hedging, and fund operations (admins, audits, valuations, LP reporting).

Adv. Amit Ashur

Legal Partner, Structuring & Transactions

Structures and executes deal frameworks; issues crisp legal opinions; leads diligence and negotiations; aligns governance, securities, and regulatory compliance; locks down risk and closes—grounded in deep cross-border M&A and financing experience.

Kim Soung

Head of Research, Data & AI

Leads models, market maps, proprietary signals, and AI-powered tools. Converts data into conviction and risk controls, surfacing anomalies and inefficiencies before markets do.